# CKD Treatment Research Findings

Research agent monitoring chronic kidney disease treatment developments.

---

## How to Use This File

- New findings are added at the top
- Each finding includes: date found, title, link, brief description, relevance
- Organized by run date
- Review during check-ins or reference as needed

---

## Run: January 24, 2026

### New Drug Treatments

**[6 New Kidney Disease Medications Approved 2025](https://www.kidney.org/news-stories/6-new-kidney-disease-medications-approved-2025)** - National Kidney Foundation
- Semaglutide (Ozempic) approved to protect kidneys in adults with type 2 diabetes and CKD
- Voyxact (sibeprenlimab-szsi) approved for IgAN
- **Relevance:** HIGH - FDA approvals, immediately actionable

**[Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes](https://www.nejm.org/doi/full/10.1056/NEJMoa2403347)** - NEJM
- Risk of primary-outcome event was 24% lower in semaglutide group vs placebo
- **Relevance:** HIGH - NEJM peer-reviewed, major clinical trial results

**[Finerenone with Empagliflozin in CKD and Type 2 Diabetes](https://www.nejm.org/doi/full/10.1056/NEJMoa2410659)** - NEJM
- Combination therapy led to greater reduction in urinary albumin-to-creatinine ratio than either alone
- **Relevance:** HIGH - NEJM, combination therapy breakthrough

**[Empagliflozin in Patients with Chronic Kidney Disease](https://www.nejm.org/doi/full/10.1056/NEJMoa2204233)** - NEJM
- Established efficacy data for empagliflozin
- **Relevance:** HIGH - NEJM peer-reviewed

### Active Clinical Trials (2026)

**[New trial: Ravulizumab for AKI Prevention](https://www.ox.ac.uk/news/2024-09-18-new-trial-test-potential-treatment-chronic-kidney-disease)** - University of Oxford
- Testing whether single dose prevents acute kidney injury in CKD patients having heart surgery
- **Relevance:** MEDIUM - Phase testing, promising mechanism

**[Vicadrostat (EASi-KIDNEY Trial)](https://clinicaltrials.ucsf.edu/chronic-kidney-disease)** - UCSF
- Aldosterone synthase inhibitor, evaluating clinical outcomes in CKD when combined with existing treatments
- **Relevance:** MEDIUM - Novel drug class (ASi), large trial

**Atacicept for IgAN**
- Showed 46% drop in proteinuria in recent study
- May be available as soon as 2026
- **Relevance:** MEDIUM - Promising results, specific to IgAN

### Behavioral Protocols & Dietary Interventions

**[Nutritional and Metabolic Interventions for Protein-Energy Wasting in Nondialysis CKD](https://www.mdpi.com/2072-6643/18/3/390)** - MDPI Nutrients (Published Jan 24, 2026)
- Adequate energy and protein intake remain cornerstone
- High-quality and plant-based proteins, oral nutritional supplements, ketoanalogues show benefits
- Physical exercise acts synergistically with dietary interventions
- **Relevance:** HIGH - Brand new (today), comprehensive review, actionable protocols

**[KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update](https://www.ajkd.org/article/S0272-6386(20)30726-5/fulltext)** - American Journal of Kidney Diseases
- Six primary areas: nutritional assessment, MNT, dietary protein/energy, supplementation, micronutrients, electrolytes
- Sodium <100 mmol/d (<2.3 g/d) to reduce blood pressure
- Augmenting dietary potassium intake for blood pressure control
- **Relevance:** HIGH - Evidence-based guidelines, widely adopted

**[Managing Hypertension in CKD: Role of Diet and Guidelines](https://www.mdpi.com/2077-0383/14/11/3755)**
- Sodium restriction as cornerstone
- Importance of physical activity and weight management
- **Relevance:** MEDIUM - Hypertension management in CKD context

---

